@article{Muendemann2001, author = {M{\"u}ndemann, Friedhelm}, title = {eLearning county ist eine Reise wert}, series = {In: TOP : das Bildungs-Magazin der Deutschen Versicherungsakademie (2001) 1, S. 16 - 17}, journal = {In: TOP : das Bildungs-Magazin der Deutschen Versicherungsakademie (2001) 1, S. 16 - 17}, pages = {16 -- 17}, year = {2001}, language = {de} } @article{Muendemann2000, author = {M{\"u}ndemann, Friedhelm}, title = {Standards f{\"u}r Telelern-Betreuer}, series = {In: Wissensmanagement (2000) 3, S. 41 - 44}, journal = {In: Wissensmanagement (2000) 3, S. 41 - 44}, pages = {41 -- 44}, year = {2000}, language = {de} } @inproceedings{Muendemann2000, author = {M{\"u}ndemann, Friedhelm}, title = {TeleCoaches: Aufgaben, Ausbildung}, series = {In: Campus 2000 : Lernen in neuen Organisationsformen / [Ges. f{\"u}r Medien in der Wissenschaft]. Friedrich Scheuermann (Hrsg.). - M{\"u}nster [u.a.] : Waxmann, 2000. - (Medien in der Wissenschaft ; 10) ISBN 3-89325-925-2}, booktitle = {In: Campus 2000 : Lernen in neuen Organisationsformen / [Ges. f{\"u}r Medien in der Wissenschaft]. Friedrich Scheuermann (Hrsg.). - M{\"u}nster [u.a.] : Waxmann, 2000. - (Medien in der Wissenschaft ; 10) ISBN 3-89325-925-2}, pages = {411 -- 413}, year = {2000}, language = {de} } @inproceedings{Muendemann1999, author = {M{\"u}ndemann, Friedhelm}, title = {Kommunikationsmanagement in Telelern-Szenarien}, series = {In: LearnTec 99 : 7. Europ{\"a}ischer Kongreß und Fachmesse f{\"u}r Bildungs- und Informationstechnologie; Tagungsband; [Karlsruhe, 9. - 11. Februar 1999] / Uwe Beck ... (Hrsg.). - Karlsruhe : Karlsruher Kongreß- und Ausstellungs-GmbH, 1999. - Karlsruhe : Karlsruher Kongreß- und Ausstellungs-GmbH, 1999. - (Schriftenreihe der Karlsruher Kongreß- und Ausstellungs-GmbH)}, booktitle = {In: LearnTec 99 : 7. Europ{\"a}ischer Kongreß und Fachmesse f{\"u}r Bildungs- und Informationstechnologie; Tagungsband; [Karlsruhe, 9. - 11. Februar 1999] / Uwe Beck ... (Hrsg.). - Karlsruhe : Karlsruher Kongreß- und Ausstellungs-GmbH, 1999. - Karlsruhe : Karlsruher Kongreß- und Ausstellungs-GmbH, 1999. - (Schriftenreihe der Karlsruher Kongreß- und Ausstellungs-GmbH)}, pages = {569 -- 580}, year = {1999}, language = {de} } @article{Luethy1998, author = {L{\"u}thy, Anja}, title = {Internet - Schl{\"u}ssel zur Kommunikation und Information des Krankenhauses}, series = {In: Managment \& Krankenhaus (1998)3,}, journal = {In: Managment \& Krankenhaus (1998)3,}, year = {1998}, language = {de} } @incollection{Luethy1998, author = {L{\"u}thy, Anja}, title = {Personalarbeit im Internet}, series = {In: Personal-Jahrbuch 1998 : Wegweiser f{\"u}r zeitgem{\"a}ße Personalarbeit. - Neuwied : Luchterhand, 1998. - ISBN 3-472-03049-6}, booktitle = {In: Personal-Jahrbuch 1998 : Wegweiser f{\"u}r zeitgem{\"a}ße Personalarbeit. - Neuwied : Luchterhand, 1998. - ISBN 3-472-03049-6}, year = {1998}, language = {de} } @article{Luethy1998, author = {L{\"u}thy, Anja}, title = {Was das Internet der Pflege bietet, Teil 1}, series = {In: Heilberufe 52(1998)2}, journal = {In: Heilberufe 52(1998)2}, year = {1998}, language = {de} } @article{Luethy1998, author = {L{\"u}thy, Anja}, title = {Was das Internet der Pflege bietet, Teil 2}, series = {In: Heilberufe 52(1998)3}, journal = {In: Heilberufe 52(1998)3}, year = {1998}, language = {de} } @article{Luethy1997, author = {L{\"u}thy, Anja}, title = {Rooming-in: L{\"a}stiges {\"U}bel oder Herausforderung?}, series = {In: Heilberufe 51(1997)11}, journal = {In: Heilberufe 51(1997)11}, year = {1997}, language = {de} } @article{Luethy1997, author = {L{\"u}thy, Anja}, title = {F{\"u}hrungskr{\"a}fte aus der Pflege}, series = {In: F{\"u}hren und Wirtschaften im Krankenhaus : F \& W (1997)5, S. 413-415}, journal = {In: F{\"u}hren und Wirtschaften im Krankenhaus : F \& W (1997)5, S. 413-415}, year = {1997}, language = {de} } @article{Luethy1997, author = {L{\"u}thy, Anja}, title = {Nutzungsm{\"o}glichkeiten des Internet im Krankenhaus}, series = {In: F{\"u}hren und Wirtschaften im Krankenhaus : F \& W (1997)2, S. 121-128}, journal = {In: F{\"u}hren und Wirtschaften im Krankenhaus : F \& W (1997)2, S. 121-128}, year = {1997}, language = {de} } @article{Luethy2006, author = {L{\"u}thy, Anja}, title = {Zeitmanagement f{\"u}r niedergelassene An{\"a}sthesisten}, series = {An{\"a}sthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : ains 41(2006)7/8, S. 514-518}, journal = {An{\"a}sthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : ains 41(2006)7/8, S. 514-518}, year = {2006}, language = {de} } @article{Mieke2012, author = {Mieke, Christian}, title = {Strategische Planung von Prozessvarianten mittels Prozess-Roadmapping}, series = {In: Industrie-Management : Zeitschrift f{\"u}r industrielle Gesch{\"a}ftsprozesse Bd. 28 (2012), 4, S.47-50. - ISSN 0179-2679,}, journal = {In: Industrie-Management : Zeitschrift f{\"u}r industrielle Gesch{\"a}ftsprozesse Bd. 28 (2012), 4, S.47-50. - ISSN 0179-2679,}, pages = {47 -- 50}, year = {2012}, language = {de} } @article{Mieke2012, author = {Mieke, Christian}, title = {Innovationsplanung mit portfoliogest{\"u}tzten Technologie-Roadmaps}, series = {In: Wissensmanagement (2012), 4, S. 14-16 . - ISSN: 1438-4426}, journal = {In: Wissensmanagement (2012), 4, S. 14-16 . - ISSN: 1438-4426}, pages = {14 -- 16}, year = {2012}, language = {de} } @book{Mieke2006, author = {Mieke, Christian}, title = {Technologiefr{\"u}haufkl{\"a}rung in Netzwerken}, publisher = {Dt. Univ.-Verl.}, address = {Wiesbaden}, isbn = {978-3-8350-0445-0}, pages = {XX, 255}, year = {2006}, subject = {Technologiemanagement}, language = {de} } @phdthesis{Mieke2005, author = {Mieke, Christian}, title = {Kooperative Technologiefr{\"u}haufkl{\"a}rung mittels szenariobasiertem Technologie-Roadmapping}, url = {http://nbn-resolving.de/urn:nbn:de:kobv:co1-000000795}, pages = {XX, 252 Bl.}, year = {2005}, language = {de} } @misc{OPUS4-342, title = {Studienf{\"u}hrer 2013/14}, editor = {Wieneke-Toutaoui, Burghilde}, publisher = {Fachhochschule Brandenburg}, address = {Brandenburg}, isbn = {978-3-9808266-5-5}, url = {http://nbn-resolving.de/urn:nbn:de:kobv:522-opus4-3420}, pages = {116}, year = {2013}, abstract = {Inhalt Allgemeine Informationen 1 Willkommen auf dem Campus (FHB) 6 Unser Studienangebot auf einen Blick 9 Die drei Fachbereiche im {\"U}berblick 10 Optimale Studienbedingungen 12 Vielf{\"a}ltige Serviceleistungen 14 Studierende im Gespr{\"a}ch 17 Beratung und Betreuung 20 Besuchertage 24 Zugang zum Studium 26 Informatik und Medien studieren 28 Fachbereich Informatik und Medien 30 Applied Computer Science (B.Sc.) 31 Informatik (B.Sc.) 35 Medizininformatik (B.Sc.) 39 Digitale Medien (M.Sc.) 42 Informatik (M.Sc.) 44 Technik studieren 48 Fachbereich Technik 50 IT-Elektronik (B.Eng.) 51 Maschinenbau (B.Eng.) 55 Mechatronik/Automatisierungssysteme (B.Eng.) 60 Mikrosystemtechnik und Optische Technologien (B.Eng.) 63 Energieeffizienz Technischer Systeme (M.Eng.) 67 Photonik (M.Eng.) 70 Wirtschaft studieren 72 Fachbereich Wirtschaft 74 Betriebswirtschaftslehre, Gr{\"u}nden - F{\"u}hren - Steuern (B.Sc.) 75 Wirtschaftsinformatik (B.Sc.) 79 Betriebswirtschaftslehre, Innovativ - Integrativ - International (M.Sc.) 82 Security Management (M.Sc.) 85 Technologie- und Innovationsmanagement (M.Sc.) 88 Wirtschaftsinformatik (M.Sc.) 90 Fernstudium/Weiterbildung 92 Lebenslang lernen 94 Berufsbegleitender Bachelorstudiengang BWL (B.A.) 95 Onlinestudiengang Medieninformatik (B.Sc.) 100 Onlinestudiengang Medieninformatik (M.Sc.) 102 Security Management (M.Sc.) 104 Studienvorbereitungskurse 106 Weiterbildung f{\"u}r Ingenieure 107 Studentenleben 108 Kontaktliste 112 Abk{\"u}rzungsverzeichnis 116 Anfahrtsplan in Brandenburg an der Havel 119 Campusplan 118 Impressum 119}, language = {de} } @misc{OPUS4-343, title = {Studienf{\"u}hrer Bachelor 2017/18}, publisher = {Technische Hochschule Brandenburg}, address = {Brandenburg an der Havel}, organization = {Technische Hochschule Brandenburg}, issn = {2196-5242}, pages = {140}, year = {2017}, language = {de} } @article{BeckBittlKolleretal.1999, author = {Beck, Eberhard and Bittl, A. and Koller, S. and Merkle, E. and Katalinic, A. and J{\"a}ger, W. and Lang, N.}, title = {Erfassung der fetalen Retardierung mittels Ponderal Index und Gewichtsperzentilen Assessment of Fetal Retardation via Ponderal Index and Weight Percentiles}, series = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, journal = {In: Geburtsh Frauenheilk 59(1999)2, 62-69}, pages = {62 -- 69}, year = {1999}, abstract = {Zusammenfassung Intrauterin wachstumsretardierte Neugeborene konnten ihr genetisches Wachstumspotential aufgrund einer intrauterinen Mangelversorgung nicht realisieren und werden deshalb zu klein oder zu leicht geboren. Das Merkmal „zu leicht" wird mit Hilfe von Gewichtsperzentilen quantifiziert. Kinder mit einem Gewicht< 10. Perzentile werden als „small for gestational age" (SGA) bezeichnet. Diese Einteilung ber{\"u}cksichtigt jedoch nicht die Proportionen eines Neugeborenen, so daß vor allem asymmetrisch retardierte Neugeborene, deren Gewicht zwar die 10. Perzentile noch {\"u}berschreitet, die jedoch f{\"u}r ihre K{\"o}rpergr{\"o}ße untergewichtig sind, nicht erfaßt werden. Der Ponderal Index (PI) dagegen ber{\"u}cksichtigt sowohl Gewicht als auch L{\"a}nge des Neugeborenen. Kinder mit einem PI < 10. Perzentile werden als „low Ponderal Index" (LPI) klassifiziert. Aus p{\"a}diatrischen Studien ist bekannt, daß LPI-Kinder vermehrt durch Hypoglyk{\"a}mien, Hypothermien, Hypokalz{\"a}mien und Mekoniumaspirationen/Aspirationspneumonien gef{\"a}hrdet sind. Langzeiterhebungen zeigten eine verz{\"o}gerte k{\"o}rperliche Entwicklung und geh{\"a}uft motorische oder neurologische Verhaltensauff{\"a}lligkeiten sowie schulische Probleme. Fragestellung: Ziel der vorliegenden Arbeit war die Frage, ob Mangelgeborene, insbesondere LPI-Neugeborene, auch intrapartum einer erh{\"o}hten Gef{\"a}hrdung ausgesetzt sind. Methoden: Hierzu wurden 3687 Neugeborene retrospektiv erfaßt, die anhand von Perzentilenkurven des betrachteten Kollektivs als SGA, LPI, SGA/LPI oder Vergleichskollektiv klassifiziert wurden. Ergebnisse: Unterschiede im Geburtsmodus zwischen SGA- bzw. LPI-Mangelgeborenen und eutrophen Neugeborenen waren schwach ausgepr{\"a}gt. Demgegen{\"u}ber unterschied sich die Indikation, aufgrund deren ein geburtshilflicher Eingriff vorgenommen werden mußte deutlich. Bei 31 \% aller operativ entbundenen LPI-Neugeborenen, 47 \% der SGA-Neugeborenen und 52 \% der SGA/LPI-Kinder erfolgte die operative Entbindung aus fetaler Indikation, im Vergleich zu 16 \% des Normalkollektivs. Bez{\"u}glich des „fetal outcome", das die Merkmale neonataler S{\"a}ure-Basen-Status, Apgar-Wert, Verlegung in die Kinderklinik und perinatale Mortalit{\"a}t einbezog, verhielten sich die Gruppen SGA, LPI und SGA/LPI in gleicher Weise schlechter gegen{\"u}ber dem Vergleichskollektiv. Die Unterschiede zwischen proportionierten (SGA) und dysproportionierten (LPI) Mangelgeborenen waren weniger deutlich. Schlußfolgerungen: Es zeigte sich, daß das gegenw{\"a}rtige engmaschige, geburtshilfliche Management mit nahezu permanenter CTG-{\"U}berwachung sub partu Probleme rechtzeitig erkennen und beherrschen ließ. Die Erfassung des niedrigen Ponderal Index war zur Erkennung und Vermeidung subpartaler geburtshilflicher Risikofaktoren nicht entscheidend.}, language = {de} } @article{BeckMoldenhauerMerkleetal.1998, author = {Beck, Eberhard and Moldenhauer, A. and Merkle, E. and Kiesewetter, F. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {CA 125 production an release by ovarian cancer cell lines in vitro}, series = {In: The international journal of biological markers 13(1998), 200 - 206}, journal = {In: The international journal of biological markers 13(1998), 200 - 206}, pages = {200 -- 206}, year = {1998}, language = {en} } @article{FehmBeckValeriusetal.1998, author = {Fehm, T. and Beck, Eberhard and Valerius, T. and Gramatzki, M. and J{\"a}ger, W.}, title = {CA 125 elevations in patients with malignant lymphomas}, series = {In: Tumor Biology 19(1998), 283 - 289}, journal = {In: Tumor Biology 19(1998), 283 - 289}, pages = {283 -- 289}, year = {1998}, language = {en} } @article{BeckWagnerAnselminoetal.1997, author = {Beck, Eberhard and Wagner, Maren and Anselmino, Lisa and Xu, Feng-ji and Bast Jr., Robert C. and J{\"a}ger, Wolfram}, title = {Is OVX1 a suitable marker for endometrial cancer?}, series = {In: Gynecologic Oncology 65(1997) 2, 291-296}, journal = {In: Gynecologic Oncology 65(1997) 2, 291-296}, pages = {291 -- 296}, year = {1997}, abstract = {The single most common cause leading to the diagnosis of endometrial cancer is postmenopausal bleeding. Although most patients with early-stage disease (FIGO stage I and II) can be cured, prognosis worsens considerably with increasing stage. While serum CA 125 levels are elevated only in a significant proportion of patients with advanced disease, recently a new serum marker (OVX1) for the detection of early-stage endometrial cancer was reported. Serum OVX1 levels were measured using an OVX1 radioimmunoassay (RIA) or enzyme immunoassay (EIA) in 192 patients with endometrial cancer. CA 125 levels were measured in 112 patients using the CIS ELSA CA 125 kit. Apparently healthy females had mean serum OVX1 levels measured with the OVX1-EIA of 1.34 ± 0.74 U/ml, while patients with endometriosis had mean OVX1 serum levels of 3.15 ± 2.45 U/ml. The mean OVX1 serum level for endometrial cancer patients was 2.00 ± 1.32 U/ml. These values were 2.76 ± 1.62, 6.10 ± 4.66, and 5.37 ± 3.49, respectively, using the OVX1-RIA assay. Applying a cutoff value of 2.8 U/ml, serum OVX1-EIA levels in endometrial cancer patients were increased in 25 of 127 patients (19.7\%) with stage I disease, 5 of 17 patients with stage II (29.4\%), 5 of 22 patients (22.7\%) with stage III, and 4 of 11 patients (36.4\%) with stage IV disease. Using the OVX1-RIA and a cutoff of 7.2 U/ml, serum levels were increased in 22 of 127 (17.3\%) stage I, 6 of 17 (35.3\%) stage II, 5 of 22 (22.7\%) stage III, and 6 of 11 (54.5\%) stage IV patients. Serum CA 125 levels, determined in a total of 112 patients, were elevated above 35 U/ml in 12 of 79 patients (15.2\%) with stage I, 4 of 12 patients (33.3\%) with stage II, 8 of 13 patients (61.5\%) with stage III, and all of 8 patients (100\%) with stage IV disease. While a good correlation between serum CA 125 levels and the clinical stage of the disease was found, no correlation could be detected for OVX1 and stage.}, language = {en} } @article{JaegerSauerbreiBecketal.1995, author = {J{\"a}ger, W. and Sauerbrei, W. and Beck, Eberhard and Maassen, V. and Stumpfe, M. and Meier, W. and Kuhn, W. and J{\"a}nicke, F.}, title = {Unbound MEDLINE A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer}, series = {In: Anticancer Research 15(1995)6B, 2639-2642}, journal = {In: Anticancer Research 15(1995)6B, 2639-2642}, issn = {0250-7005}, pages = {2639 -- 2642}, year = {1995}, language = {en} } @incollection{BeckMoldenhauerKiesewetteretal.1994, author = {Beck, Eberhard and Moldenhauer, A. and Kiesewetter, F. and J{\"a}ger, W. and Woldt, L. and Lang, N.}, title = {Analysis of CA 125 production and release by ovarian cancer cells in vitro}, series = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, booktitle = {In: Current tumor diagnosis : applications, clinical relevance, research - trends / 7th Symposium on Tumor Markers, Hamburg 1993 ; Satellite Symposium Cancer of the Lung - State and Trends in Diagnosis and Therapy. Ed. by R. Klapdor. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1994. - ISBN 3-88603-509-3}, pages = {187 -- 191}, year = {1994}, language = {en} } @article{BeckHofmannBernhardtetal.1994, author = {Beck, Eberhard and Hofmann, M. and Bernhardt, G. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {In vitro activity of immunoconjugates between cisplatin and an anti CA125 monoclonal antibody on ovarian cancer cell lines}, series = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, journal = {In: Cell Biophysics 24/25(1994)1-3, 163-173}, issn = {0163-4992}, pages = {163 -- 173}, year = {1994}, abstract = {Cis-diammine dichloro platinum (II) (CDDP), is a highly potent antineoplastic agent that is used in the treatment of ovarian cancer. However, the clinical use of CDDP is restricted by its severe side effects. In order to reduce these side effects and to enhance its therapeutic efficacy, we developed specific immunoconjugates consisting of the murine monoclonal antibody OC125 and CDDP, using diethylene triamine pentaacetic acid (DTPA) as a linker. The coupling efficiencies of the different preparations synthesized, varied between 1.10±0.42 and 2.65±1.60 mol of CDDP per mol of antibody protein. Despite the chemical modification of the antibody molecule, specific binding activity of the OC125-CDDP conjugates toward the CA125 antigen was maintained as was demonstrated by means of immunohisto-/cytochemical staining of frozen sections of ovarian cancer tissue, amniotic epithelium, and the CA125 positive ovarian cancer cell line NIH:OVCAR 3. The antiproliferative activity of the immunoconjugates was tested against the human ovarian cancer cell lines NIH:OVCAR3 and SKOV 3, applying a kinetic crystal violet microassay. Despite the promising results obtained with the specific immuno-staining of the target cells, no significant antiproliferative activity of our immunoconjugates against the cell lines tested was observed. One possible explanation for the lack of antitumor activity could be the fact that CA125 is released in large amounts by the NIH:OVCAR 3 cells. This may have prevented an efficient immunotargeting of the cancer cells by the formation of soluble immune complexes.}, language = {en} } @article{BeckRussoGliozzoetal.1994, author = {Beck, Eberhard and Russo, Pietro and Gliozzo, Biancamaria and J{\"a}ger, Wolfram and Papa, Vincenzo and Wildt, Ludwig and Pezzino, Vincenzo and Lang, Norbert}, title = {Identification of insulin and insulin-like growth factor I (IGF I) receptors in ovarian cancer}, series = {In: Gynecologic Oncology 53(1994)2, 196-201}, journal = {In: Gynecologic Oncology 53(1994)2, 196-201}, issn = {0090-8258}, pages = {196 -- 201}, year = {1994}, abstract = {Abstract The objective of this study was to test if specific insulin and insulin-like growth factor I (IGF I) receptors are expressed in ovarian cancer tissue. Thirteen tissue specimens from primary ovarian cancers, 1 specimen from a primary peritoneal carcinoma, 10 specimens from metastatic lesions of ovarian carcinomas, and 4 specimens from recurrent ovarian cancers together with 13 normal ovaries were tested for their content of insulin and IGF-I receptors, by the application of specific insulin and IGF-I receptor radioimmunoassays. The insulin receptor (IR) and IGF-I receptor (IGF R) content in the primary tumors varied between 23.8-321.4 and 16.4-554.2 ng/0.1 mg DNA, respectively. Metastatic lesions contained between 12.3 and 226.7 ng IR/0.1 mg DNA and between 7.5 and 459.4 ng IGF R/0.1 mg DNA. In recurrent tumors the receptor concentrations were in the range of 41.5-79.8 and 48.9-160.9 ng/0.1 mg DNA for insulin and IGF-I receptors, respectively. Normal ovarian tissue contained between 12.2 and 150.1 ng IR and between 21.4 and 420.1 ng IGF R per 0.1 mg DNA, respectively. As both insulin and IGF-I receptors are present in ovarian cancer tissue, the effects of insulin and IGF-I as potential growth factors in ovarian cancer should be further investigated. Copyright © 1994 Academic Press. All rights reserved.}, language = {en} } @article{BeckRussoPapaetal.1993, author = {Beck, Eberhard and Russo, P. and Papa, V. and J{\"a}ger, W. and Pezzino, V. and Wildt, L. and Vigneri, R. and Lang, N.}, title = {Nachweis von Insulin-Rezeptoren (IR) in Ovarialkarzinomgewebe}, series = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, journal = {In: Archives of Gynecology and Obstetrics December 254(1993)Iss. 1-4, 1053-1054}, issn = {0932-0067}, pages = {1053 -- 1054}, year = {1993}, language = {de} } @incollection{BittlBeckJaegeretal.1993, author = {Bittl, A. and Beck, Eberhard and J{\"a}ger, W. and Wildt, L.}, title = {Untersuchungen zur Amenorrhoe unter adjuvanter CMF-Chemotherapie bei Mammakarzinom-Patientinnen}, series = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992; 26 Tabellen / Bd.-Hrsg.: N. Lang; W. J{\"a}ger. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - (Aktuelle Onkologie ; 68). - ISBN: 3-88603-458-5}, booktitle = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992; 26 Tabellen / Bd.-Hrsg.: N. Lang; W. J{\"a}ger. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - (Aktuelle Onkologie ; 68). - ISBN: 3-88603-458-5}, pages = {10 -- 14}, year = {1993}, language = {de} } @inproceedings{Muendemann1999, author = {M{\"u}ndemann, Friedhelm}, title = {Kommunikationsmanagement in Telelern-Szenarien}, series = {In: Berufsbildung '99 : fit im Beruf - fit f{\"u}r die Zukunft ; Dokumentation ; N{\"u}rnberg 1. bis 4. Dezember 1999 / [Fachausstellung f{\"u}r Aus- und Weiterbildung und 7. Bayerischer Berufsbildungskongress]. - M{\"u}nchen : Bayerisches Staatsministerium f{\"u}r Arbeit und Sozialordnung, Familie, Frauen und Gesundheit, 1999. - (Studien und Berichte zur Berufsbildung)}, booktitle = {In: Berufsbildung '99 : fit im Beruf - fit f{\"u}r die Zukunft ; Dokumentation ; N{\"u}rnberg 1. bis 4. Dezember 1999 / [Fachausstellung f{\"u}r Aus- und Weiterbildung und 7. Bayerischer Berufsbildungskongress]. - M{\"u}nchen : Bayerisches Staatsministerium f{\"u}r Arbeit und Sozialordnung, Familie, Frauen und Gesundheit, 1999. - (Studien und Berichte zur Berufsbildung)}, pages = {160 -- 161}, year = {1999}, language = {de} } @article{Muendemann1998, author = {M{\"u}ndemann, Friedhelm}, title = {Online only?}, series = {In: Das Forum : Zeitschr. d. Volkshochschulen Bayerns, (1998) 2, S. 2-9 ISSN 0176-3687}, journal = {In: Das Forum : Zeitschr. d. Volkshochschulen Bayerns, (1998) 2, S. 2-9 ISSN 0176-3687}, pages = {2 -- 9}, year = {1998}, subject = {Mediendidaktik}, language = {de} } @article{Luethy2012, author = {L{\"u}thy, Anja}, title = {Employer Branding: Was Kliniken von anderen Branchen lernen k{\"o}nnen}, series = {In: HeilberufeScience 3 (2012), S. 18}, journal = {In: HeilberufeScience 3 (2012), S. 18}, pages = {18}, year = {2012}, language = {de} } @incollection{BuchmannLuethy2012, author = {Buchmann, Uta and L{\"u}thy, Anja}, title = {Umfassendes Dienstleistungsmarketing - Pflichtaufgabe f{\"u}r Krankenh{\"a}user}, series = {In: Patient Krankenhaus : Wie Kliniken der Spagat zwischen {\"O}konomie und medizinischer Spitzenleistung gelingt / hrsg. von Ulrich Korff. - Wiesbaden : Gabler, 2012. - ISBN: 978-3-8349-7189-0; 978-3-8349-3433-8 (ISBN der Printausgabe)}, booktitle = {In: Patient Krankenhaus : Wie Kliniken der Spagat zwischen {\"O}konomie und medizinischer Spitzenleistung gelingt / hrsg. von Ulrich Korff. - Wiesbaden : Gabler, 2012. - ISBN: 978-3-8349-7189-0; 978-3-8349-3433-8 (ISBN der Printausgabe)}, pages = {177 -- 191}, year = {2012}, abstract = {Krankenh{\"a}user m{\"u}ssen noch viel lernen, wenn es darum geht, ihre Leistungen kundenorientiert - auch {\"u}ber die medizinischen Kernleistungen hinaus - erfolgreich zu vermarkten. Von einem systematischen Dienstleistungsmarketing sind viele H{\"a}user noch weit entfernt. Ein professionell praktiziertes Dienstleistungsmarketing - von der grundlegenden Strategie bis zur operativen Umsetzung - ist jedoch die Grundvoraussetzung, um sich im Wettbewerb um Patienten erfolgreich zu behaupten.}, language = {de} } @article{GebauerMuellerFehmetal.2004, author = {Gebauer, Gerhard and Mueller, Natalia and Fehm, Tanja and Berkholz, Alexander and Beck, Eberhard and Jaeger, Wolfram and Licht, Peter}, title = {Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors in ovarian cancer and its correlation to human chorionic gonadotropin-doxorubicin sensitivity}, series = {In: American Journal of Obstetrics \& Gynecology 190 (2004), Iss. 6, pp. 1621-1628}, journal = {In: American Journal of Obstetrics \& Gynecology 190 (2004), Iss. 6, pp. 1621-1628}, pages = {1621 -- 1624}, year = {2004}, abstract = {Objective Ovarian cancer cell lines and tissues express gonadotropin receptors. Conjugation of cytostatics to ligands of these receptors may increase the specificity of cytotoxic drugs. Study design Toxicity of doxorubicin-human chorionic gonadotropin conjugates was determined in 4 ovarian cancer cell lines. Expression and regulation of luteinizing hormone/human chorionic gonadotropin receptors were analyzed before and after treatment with human chorionic gonadotropin, epidermal growth factor, and 8-bromo-cyclic adenosine monophosphate with a nested reverse transcriptase-polymerase chain reaction approach. Results Toxicity of human chorionic gonadotropin-doxorubicin conjugates was increased compared with unconjugated doxorubicin in OVCAR-3 cells. However, drug conjugates failed to demonstrate increased toxicity in other cell lines, especially after preincubation with human chorionic gonadotropin. All cell lines expressed luteinizing hormone/human chorionic gonadotropin receptors. Receptor expression in OVCAR-3 cells was not effected by human chorionic gonadotropin, endothelial growth factor, or 8-bromo-cyclic adenosine monophosphate treatment. In other cell lines, receptor expression was down-regulated by these agents. Conclusion Cytotoxic activity of doxorubicin was increased specifically by conjugation to human chorionic gonadotropin. However, the regulation of luteinizing hormone/human chorionic gonadotropin receptor expression and other compounds may reduce the drug-uptake of the conjugates.}, language = {en} } @article{GebauerFehmBecketal.2003, author = {Gebauer, Gerhard and Fehm, Tanja and Beck, Eberhard and Berkholz, Alexander and Licht, Peter and J{\"a}ger, Wolfram}, title = {Cytotoxic effect of conjugates of doxorubicin and human chorionic gonadotropin (hCG) in breast cancer cells}, series = {In: Breast Cancer Research and Treatment 77(2003)2, pp. 125-131}, journal = {In: Breast Cancer Research and Treatment 77(2003)2, pp. 125-131}, pages = {125 -- 131}, year = {2003}, abstract = {Cytotoxic activity of drug conjugates of human chorionic gonadotropin (hCG) and doxorubicin alone was investigated compared to doxorubicin in breast cancer cells with and without expression of hCG receptors. Expression of hCG receptor was determined in MCF-7 and MB231 breast cancer cell line using a multiplex nested rt-PCR approach. The entire sequence of mRNA encoding for hCG receptor was detected in MCF-7 but not in MB231 breast cancer cell line. Cytostatic effect of doxorubicin-hCG conjugates was investigated in these cell lines in comparison to unconjugated doxorubicin. The number of viable cells was determined after 24, 48, 72, 96, and 120 h. To exclude non-specific uptake of the carrier hCG from the culture media, a similar experiment was performed with albumin-doxorubicin conjugates. The number of viable cells decreased in a concentration depending manner after doxorubicin and hCG-doxorubicin conjugate treatment. However, the cytotoxic effect of hCG-doxorubicin conjugate was 10-fold increased compared to unconjugated doxorubin in hCG-receptor positive MCF-7 but not in hCG-receptor negative MB231 cells. Albumin-doxorubicin conjugates showed no increased toxicity compared to doxorubicin. We conclude that the cytotoxic effect of hCG-doxorubicin conjugates is mediated specifically via the hCG receptor. By using hCG conjugates, the development of more selective cytostatics can be achieved.}, language = {en} } @article{GebauerFehmMerkleetal.2001, author = {Gebauer, Gerhard and Fehm, Tanja and Merkle, Elisabeth and Beck, Eberhard and Lang, Norbert and J{\"a}ger, Wolfram}, title = {Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-Up}, series = {In: J. Clin. Oncol. 19(2001)16, 3669 - 3674}, journal = {In: J. Clin. Oncol. 19(2001)16, 3669 - 3674}, pages = {3669 -- 3674}, year = {2001}, abstract = {PURPOSE: To evaluate the detection of epithelial cells in bone marrow of breast cancer patients as an indicator of metastatic disease. PATIENTS AND METHODS: Between 1989 and 1994, bone marrow biopsies were performed on 393 breast cancer patients during primary surgery. Specimens were stained immunocytochemically for epithelial cells expressing cytokeratins or the epithelial membrane antigen. The long-term outcomes of these patients were analyzed in this study. RESULTS: In 166 of 393 patients, epithelial cells were found in bone marrow (BM) aspirates. These patients were designated BM+. The rate of tumor recurrence or cancer-related death was significantly higher in BM+ patients than in BM- patients. Multivariate analysis using the Cox regression model revealed BM status as a prognostic parameter independent of tumor size and axillary lymph node status. However, tumor size and axillary lymph node status were clearly superior prognostic parameters. CONCLUSION: Disseminated epithelial cells in BM are associated with poor clinical outcome in breast cancer patients. However, the presence of these cells is not a sufficient parameter to predict growing metastases in the majority of patients, suggesting that epithelial cells in the BM of breast cancer patients at the time of surgery have limited metastatic potential. The role of these cells needs to be further evaluated.}, language = {en} } @article{MerkleAckermannBecketal.2000, author = {Merkle, E. and Ackermann, S. and Beck, Eberhard and J{\"a}ger, W. and Lang, N.}, title = {High-Dose versus Low-Dose Cisplatin Chemotherapy plus Treosulfan in Epithelial Ovarian Carcinoma FIGO II-IV: Results of a Prospective Randomized Trial}, series = {In: Onkologie 23(2000)3, 232-238}, journal = {In: Onkologie 23(2000)3, 232-238}, pages = {232 -- 238}, year = {2000}, abstract = {Summary Background: Combination chemotherapies of platinum compounds with alkylating agents have been the standard treatment for patients with advanced ovarian carcinoma over the last decades. The recent development of taxans has added a group of new promising agents; however, long-term results are not yet available. Platin derivates have proven to be an indispensable part in combination chemotherapies for ovarian carcinoma. The dose intensity of cisplatin is, however, still a matter of debate. We report on the long-term results of a prospective randomized trial comparing two dosages of cisplatin combined with treosulfan in patients with advanced epithelial ovarian cancer. Patients and Methods: Between 1988 and 1995, 125 patients with ovarian cancer (FIGO stage II-IV) were randomized to receive 4 cycles (28-day intervals) of either cisplatin 100 mg/m2 (high dose, HD) or 50 mg/m2 (low dose, LD) in combination with 5 g/m2 treosulfan after primary cytoreductive surgery. Postoperative residual tumor was absent in 39 patients (HD: 16; LD: 23), < 2 cm in 61 patients (HD: 36; LD: 25) and > 2 cm in 25 patients (HD: 13; LD: 12). 65 and 60 patients received HD and LD cisplatin, respectively. Second-look surgery was optional. Results:The overall response rate was 70.0\% (HD: 70.9\%; LD: 68.9\%). Pathological complete response (CR) was seen in 45 patients (37.5\%), clinical CR in 23 patients (19.2\%), partial response (PR) in 16 patients (13.3\%), stable disease (SD) in 2 patients, and progression of disease (PD) in 34 patients (28.3\%). 5 patients were not assessable for response. Overall median survival was 25.6 (HD: 26.9, LD: 25.2) months. The overall disease-free survival for responders was 19.6 and 24.7 months (HD and LD, respectively). HD chemotherapy did not result in any significant survival benefit in completely resected patients: HD: 39.8 months versus LD: 49.5 months. In suboptimally debulked patients (residual tumor < 2 cm), median survival was 24.1 months (HD) versus 22.6 months (LD). In patients with residual tumors > 2 cm median survival was 14.6 months (HD) versus 15.5 months (LD). Significantly less side effects were seen in the LD group: anemia (p = 0.008); nephrotoxicity (p = 0.014); alopecia (p = 0.017). Conclusions: Our data suggest that LD cisplatin-based chemotherapy is as effective as HD chemotherapy in patients with advanced epithelial ovarian cancer, but is far less toxic. Copyright © 2000 S. Karger GmbH, Freiburg}, language = {en} } @incollection{BeckSciaccaPandinietal.2001, author = {Beck, Eberhard and Sciacca, Laura and Pandini, Giuseppe and Jaeger, Wolfram and Pezzino, Vincenzo}, title = {Measurement of IGF-1 Receptor Content in Tissues and Cell Lines by Radioimmunoassay (RIA) and ELISA Techniques}, series = {In: Ovarian Cancer : Methods and Protocols / ed. by John M. S. Bartlett. - Totowa, NJ : Humana Press, 2001. - Totowa, NJ : Humana Press, 2001. - (Methods in Molecular Medicine™ ; 39). - ISBN: 978-1-592-59071-1; 978-0-89603-583-6 (ISBN der Printausgabe)}, booktitle = {In: Ovarian Cancer : Methods and Protocols / ed. by John M. S. Bartlett. - Totowa, NJ : Humana Press, 2001. - Totowa, NJ : Humana Press, 2001. - (Methods in Molecular Medicine™ ; 39). - ISBN: 978-1-592-59071-1; 978-0-89603-583-6 (ISBN der Printausgabe)}, pages = {485 -- 492}, year = {2001}, abstract = {The IGF-1 receptor (IGF-1-R) belongs to the tyrosine kinase growth factor receptor family. It is structurally similar to, but distinct from, the insulin receptor, with which it shares a 70\% homology. As expected, it crossreacts with insulin and, vice versa, insulin receptor crossreacts with IGF-1. Numerous studies suggest that IGF-1-R is very important for mitogenesis and is essential for phenotype transformation, at least in rodents (1). In particular, the IGF-1-R has been described in human breast cancer (2-4) and ovarian cancer (5) tissues and in cultured human breast cancer cell lines (6,7).}, language = {en} } @article{BeckVincentiLichtetal.2000, author = {Beck, Eberhard and Vincenti, D. and Licht, P. and Berkholz, A. and J{\"a}ger, W. and Lang, N. and Merkle, E.}, title = {In vitro activity of human chorionic gonadotropin (hCG)--doxorubicin conjugates against ovarian cancer cells}, series = {In: Anticancer research 20(2000)5A, pg 3001-6}, journal = {In: Anticancer research 20(2000)5A, pg 3001-6}, pages = {3001 -- 3006}, year = {2000}, abstract = {BACKGROUND Despite radical surgery and the introduction of novel chemotherapeutic agents, the prognosis of ovarian cancer remains poor. Since in the past the potential role of gonadotropins in the induction and progression of ovarian cancer has been discussed, we conjugated doxorubicin to human chorionic gonadotropin (hCG) in order to specifically target ovarian cancer cells. MATERIALS AND METHODS Doxorubicin was conjugated to hCG via glutaraldehyde. 48 hours post seeding, NIH:OVCAR 3 cells were treated with various concentrations of hCG-conjugated and non-conjugated doxorubicin for 2 hours. Cells were cultured for a total of 168 hours. Cell growth was monitored by a crystal violet assay. RESULTS Conjugating doxorubicin to hCG resulted in an average specific uptake of 22 mol doxorubicin per mol protein (range 3.0-43.3 mol). Incubating NIH:OVCAR 3 cells for 2 hours with the conjugate led to a more than 8 fold increase of the IC50 values compared to non-conjugated doxorubicin (0.55 microM versus 4.43 microM). The antiproliferative activity of both conjugated and free doxorubicin was detectable up to 168 hours post treatment. CONCLUSIONS The present experiments clearly demonstrate a more than 8-fold increase in cytotoxicity of the conjugates compared to free doxorubicin. It was also shown that this effect was not restricted to an acute toxic event but that it resulted in a prolonged antiproliferative activity.}, language = {en} } @inproceedings{ClausBeckGmeineretal.1992, author = {Claus, D. and Beck, Eberhard and Gmeiner, H.J. and Puschmann, E. and Brunh{\"o}lzl, C. and J{\"a}ger, W. and Neund{\"o}rfer, B.}, title = {Neurotoxische Nebenwirkungen von Zytostatika}, series = {In: Ophthalmoneurologie, Therapiekontrolle, Pr{\"a}vention : 65. Jahrestagung vom 23. - 26. September 1992 in Saarbr{\"u}cken/ hrsg. von K. Schimrigk ... Unter Mitwirkung von M. Grundmann ... - Berlin, 1992. - (Verhandlungen der Deutschen Gesellschaft f{\"u}r Neurologie ; 7) (Tagung / Deutsche Gesellschaft f{\"u}r Neurologie ; 65). - ISBN: 3-924171-14-9}, booktitle = {In: Ophthalmoneurologie, Therapiekontrolle, Pr{\"a}vention : 65. Jahrestagung vom 23. - 26. September 1992 in Saarbr{\"u}cken/ hrsg. von K. Schimrigk ... Unter Mitwirkung von M. Grundmann ... - Berlin, 1992. - (Verhandlungen der Deutschen Gesellschaft f{\"u}r Neurologie ; 7) (Tagung / Deutsche Gesellschaft f{\"u}r Neurologie ; 65). - ISBN: 3-924171-14-9}, pages = {738 -- 740}, year = {1992}, language = {de} } @inproceedings{BeckHofmannKiesewetteretal.1992, author = {Beck, Eberhard and Hofmann, M. and Kiesewetter, F. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {Analysis of CA 125 release by ovarian cancer cells in vitro}, series = {In: Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties / 6th Symposium on Tumor Markers, Hamburg, [December 9. - 11. 1991] ; Satellite Symposium Cancer of the Breast - State and Trends in Diagnosis and Therapy. Ed. by R. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - ISBN 3-88603-444-5}, booktitle = {In: Tumor associated antigens, oncogenes, receptors, cytokines in tumor diagnosis and therapy at the beginning of the nineties / 6th Symposium on Tumor Markers, Hamburg, [December 9. - 11. 1991] ; Satellite Symposium Cancer of the Breast - State and Trends in Diagnosis and Therapy. Ed. by R. - M{\"u}nchen [u.a.] : Zuckschwerdt, 1992. - ISBN 3-88603-444-5}, pages = {117 -- 121}, year = {1992}, language = {en} } @inproceedings{BeckSeidingerSchneideretal.1992, author = {Beck, Eberhard and Seidinger, M. and Schneider, G. A. and Schuster, M. and Berg, A. and J{\"a}ger, W. and Wildt, L. and Lang, N.}, title = {Toxische Sch{\"a}digungen des Geh{\"o}rs unter Cisplatinhaltiger Chemotherapie bei Patientinnen mit gyn{\"a}kologischen Tumoren}, series = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992 ; 26 Tabellen / Bd-Hrsg.: N. Lang ... - M{\"u}nchen [u.a.] : Zuckschwerdt, 1993. - Aktuelle Onkologie ; 8). - ISBN: 3-88603-458-5}, booktitle = {In: Zytostatikabedingte Nebenwirkungen : Symposium in Pommersfelden, 3. - 4. Juli 1992 ; 26 Tabellen / Bd-Hrsg.: N. Lang ... - M{\"u}nchen [u.a.] : Zuckschwerdt, 1993. - Aktuelle Onkologie ; 8). - ISBN: 3-88603-458-5}, pages = {5 -- 9}, year = {1992}, language = {de} } @incollection{JaegerLoefflerBecketal.1992, author = {J{\"a}ger, W. and L{\"o}ffler, B. and Beck, Eberhard and Bellmann, O. and Wolf, A. and Mund-Hoym, S. and Sauerbrei, W. and Wildt, L. and Lang, N.}, title = {Retrospective analysis of GnRH analogue administration in patients with advanced ovarian cancer}, series = {In: GnRH analogues and cancer : plus a review of the treatment of uterine leiomyomata; the proceedings of the 2. International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, November 1990 / ed. by B. Lunenfeld. - Carnforth, Lancs. [u.a.] : Parthenon Publ., 1992. - (Advances in the study of GnRH analogues ; 4). - ISBN: 1-85070-328-0}, booktitle = {In: GnRH analogues and cancer : plus a review of the treatment of uterine leiomyomata; the proceedings of the 2. International Symposium on GnRH Analogues in Cancer and Human Reproduction, Geneva, November 1990 / ed. by B. Lunenfeld. - Carnforth, Lancs. [u.a.] : Parthenon Publ., 1992. - (Advances in the study of GnRH analogues ; 4). - ISBN: 1-85070-328-0}, pages = {69 -- 76}, year = {1992}, language = {en} } @misc{OPUS4-318, title = {Lesesaal der Hochschulbibliothek}, organization = {Fachhochschule Brandenburg / Hochschulbibliothek}, url = {http://nbn-resolving.de/urn:nbn:de:kobv:522-opus4-3184}, year = {2004}, abstract = {Lesesaal 1. OG}, language = {de} } @incollection{Mieke2012, author = {Mieke, Christian}, title = {Portfoliogest{\"u}tztes Roadmapping in der Technologievorausschau}, series = {In: Interdisziplinarit{\"a}t und Komplexit{\"a}t / Konferenz f{\"u}r Wirtschafts- und Sozialkybernetik KyWi 2012 vom 28. bis 29. Juni 2012 in Aachen. [Gesellschaft f{\"u}r Wirtschafts- und Sozialkybernetik e.V. ; Institut f{\"u}r Unternehmenskybernetik]. Hrsg. von Sabina Jeschke ... - Berlin : Duncker \& Humblot , 2012. - (Wirtschaftskybernetik und Systemanalyse ; Bd. 27) 978-3-428-13955-2}, booktitle = {In: Interdisziplinarit{\"a}t und Komplexit{\"a}t / Konferenz f{\"u}r Wirtschafts- und Sozialkybernetik KyWi 2012 vom 28. bis 29. Juni 2012 in Aachen. [Gesellschaft f{\"u}r Wirtschafts- und Sozialkybernetik e.V. ; Institut f{\"u}r Unternehmenskybernetik]. Hrsg. von Sabina Jeschke ... - Berlin : Duncker \& Humblot , 2012. - (Wirtschaftskybernetik und Systemanalyse ; Bd. 27) 978-3-428-13955-2}, pages = {37 -- 44}, year = {2012}, language = {de} } @incollection{MiekeBraunisch2012, author = {Mieke, Christian and Braunisch, Dirk}, title = {Steuerungsm{\"o}glichkeiten f{\"u}r die r{\"u}ckf{\"u}hrende Logistik}, series = {In: Innovative Produktionswirtschaft : Jubil{\"a}umsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5}, booktitle = {In: Innovative Produktionswirtschaft : Jubil{\"a}umsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5}, pages = {292 -- 312}, year = {2012}, language = {de} } @book{OPUS4-328, title = {Innovative Produktionswirtschaft : Jubil{\"a}umsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus}, editor = {Mieke, Christian}, publisher = {Logos-Verl.}, address = {Berlin}, isbn = {978-3-8325-3177-5}, pages = {X, 358 S.}, year = {2012}, subject = {Produktionswirtschaft}, language = {de} } @incollection{Mieke2012, author = {Mieke, Christian}, title = {Prozess-Roadmapping - Werkzeug zur Planung von Prozess-Innovationen}, series = {In: Innovative Produktionswirtschaft : Jubil{\"a}umsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5}, booktitle = {In: Innovative Produktionswirtschaft : Jubil{\"a}umsschrift zu 20 Jahren produktionswirtschaftlicher Forschung an der BTU Cottbus / Christian Mieke ; Dirk Braunisch (Hrsg.) . - Berlin : Logos-Verl., 2012. - (PTI ; Bd. 2) 978-3-8325-3177-5}, pages = {101 -- 114}, year = {2012}, language = {de} } @article{LoeweDalijono2012, author = {L{\"o}we, Katharina and Dalijono, Taufan}, title = {Entwicklung eines Operatorunterst{\"u}tzungssystems zur Steigerung der Sicherheit hochautomatisierter verfahrenstechnischer Anlagen}, series = {In: Chemie Ingenieur Technik / Special Issue: 60 Jahre GVT 84 (2012) 11, 2027-2034}, journal = {In: Chemie Ingenieur Technik / Special Issue: 60 Jahre GVT 84 (2012) 11, 2027-2034}, pages = {2027 -- 2034}, year = {2012}, language = {de} } @article{WidiputriLoeweLoeher2009, author = {Widiputri, Diah Indriani and L{\"o}we, Katharina and L{\"o}her, Heinz-Josef}, title = {Systematic approach to incorporate human factors into a process plant design}, series = {In : Process Safety Progress 28 (2009) 4, S. 347-355}, journal = {In : Process Safety Progress 28 (2009) 4, S. 347-355}, issn = {1066-8527}, pages = {347 -- 355}, year = {2009}, abstract = {Despite the increasing number of accidents in process industry caused by human error, there are still too few efforts devoted to this area. This is mainly caused by people's tendency to overestimate human's capability in interacting with their working environment and moreover by the unavailability of reliable analysis methods. Because of the current lack of adequate methods, human factors (HF) analysis is not widely performed in process industry. Some HF techniques developed in the process industry were examined regarding their practical applicability and were unfortunately proved to be unsuitable for an elaborate HF analysis. Therefore, a new approach was developed, which provides a systematic way in performing a qualitative HF analysis to achieve a safer operation and decrease the number of human failure events. HF consideration during the design of a process plant is the key to minimize accidents caused by human error in process industry. Thus, an approach to incorporate HF into design phase is described in this article, which can help achieving a safer operation as early as possible with minimized costs. © 2009 American Institute of Chemical Engineers Process Saf Prog 2009}, language = {en} } @article{LoeweKariuki2007, author = {L{\"o}we, Katharina and Kariuki, S. G.}, title = {Integrating Human Factors in the Process Hazard Analysis}, series = {In: Reliability Engineering \& System Safety 92 (2007) 12, pp 1764-1773}, journal = {In: Reliability Engineering \& System Safety 92 (2007) 12, pp 1764-1773}, issn = {0951-8320}, pages = {1764 -- 1773}, year = {2007}, language = {en} }